NASDAQ:VICL - Vical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.69 +0.05 (+3.05 %)
(As of 05/25/2018 12:30 PM ET)
Previous Close$1.68
Today's Range$1.68 - $1.69
52-Week Range$1.32 - $3.70
Volume700 shs
Average Volume141,116 shs
Market Capitalization$36.43 million
P/E Ratio-1.67
Dividend YieldN/A
Beta1.17

About Vical (NASDAQ:VICL)

Vical logoVical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the company's core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VICL
CUSIP92560210
Phone858-646-1100

Debt

Debt-to-Equity RatioN/A
Current Ratio18.27
Quick Ratio18.27

Price-To-Earnings

Trailing P/E Ratio-1.67
Forward P/E Ratio-1.56
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.82 million
Price / Sales2.67
Cash FlowN/A
Price / CashN/A
Book Value$2.67 per share
Price / Book0.63

Profitability

EPS (Most Recent Fiscal Year)($1.01)
Net Income$-12,960,000.00
Net Margins-144.80%
Return on Equity-32.93%
Return on Assets-27.09%

Miscellaneous

Employees74
Outstanding Shares21,820,000

Vical (NASDAQ:VICL) Frequently Asked Questions

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

How were Vical's earnings last quarter?

Vical (NASDAQ:VICL) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.12. The biotechnology company had revenue of $0.72 million for the quarter, compared to analyst estimates of $2.10 million. Vical had a negative return on equity of 32.93% and a negative net margin of 144.80%. View Vical's Earnings History.

When is Vical's next earnings date?

Vical is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Vical.

What price target have analysts set for VICL?

3 brokerages have issued twelve-month price targets for Vical's shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate Vical's share price to reach $7.00 in the next year. View Analyst Ratings for Vical.

Who are some of Vical's key competitors?

Who are Vical's key executives?

Vical's management team includes the folowing people:
  • Mr. Vijay B. Samant, Chief Exec. Officer, Pres and Director (Age 65)
  • Mr. Anthony Alan Ramos, Chief Financial Officer & Principal Accounting Officer (Age 51)
  • Dr. Lawrence Russell Smith Ph.D., Sr. VP of Research (Age 57)
  • Mr. Keith D. Hall M.D., VP of Operations (Age 56)
  • Dr. Mammen P. Mammen Jr., M.D., Sr. VP of Clinical Devel. (Age 54)

Has Vical been receiving favorable news coverage?

Media stories about VICL stock have trended somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vical earned a coverage optimism score of 0.07 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Vical?

Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical's stock price today?

One share of VICL stock can currently be purchased for approximately $1.69.

How big of a company is Vical?

Vical has a market capitalization of $36.43 million and generates $13.82 million in revenue each year. The biotechnology company earns $-12,960,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Vical employs 74 workers across the globe.

How can I contact Vical?

Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected]


MarketBeat Community Rating for Vical (VICL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vical (NASDAQ:VICL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Vical in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 314.20%. The high price target for VICL is $9.00 and the low price target for VICL is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$7.00$7.50
Price Target Upside: 314.20% upside360.53% upside376.19% upside278.79% upside

Vical (NASDAQ:VICL) Consensus Price Target History

Price Target History for Vical (NASDAQ:VICL)

Vical (NASDAQ:VICL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
8/8/2017Ifs SecuritiesReiterated RatingOutperformMediumView Rating Details
6/12/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$9.00HighView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Vical (NASDAQ:VICL) Earnings History and Estimates Chart

Earnings by Quarter for Vical (NASDAQ:VICL)

Vical (NASDAQ:VICL) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-1.44 EPS

Vical (NASDAQ VICL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/3/2018Q1 2018($0.17)($0.29)$2.10 million$0.72 millionViewN/AView Earnings Details
3/15/2018n/a($0.11)($0.21)$4.60 million$3.95 millionViewListenView Earnings Details
10/23/2017Q3 2017($0.25)($0.27)$3.60 million$3.24 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.28)($0.30)$3.35 million$3.42 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.18)($0.25)$3.21 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.21)($0.25)$2.92 million$3.16 millionViewListenView Earnings Details
11/3/2016Q3($0.25)($0.24)$4.60 million$2.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.28)($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.03)$6.88 million$4.60 millionViewN/AView Earnings Details
3/14/2016Q415($0.02)($0.03)$4.82 million$6.81 millionViewListenView Earnings Details
7/30/2015Q215($0.06)($0.03)$3.80 million$4.20 millionViewListenView Earnings Details
5/8/2015Q115($0.05)($0.04)$2.50 million$4.90 millionViewN/AView Earnings Details
2/26/2015Q414($0.05)($0.05)$3.58 million$4.82 millionViewN/AView Earnings Details
10/30/2014Q314($0.05)($0.05)$2.50 million$3.40 millionViewN/AView Earnings Details
7/31/2014Q214($0.05)($0.05)$1.90 million$4.50 millionViewN/AView Earnings Details
5/1/2014Q114($0.05)($0.04)$1.60 million$2.40 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)($0.03)$1.54 million$3.15 millionViewN/AView Earnings Details
10/31/2013Q313($0.10)($0.11)$1.82 million$1.50 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.11)($0.11)$1.70 million$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.11)($0.11)$2.02 million$1.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.10)($0.09)$1.64 million$2.32 millionViewN/AView Earnings Details
11/7/2012Q312($0.09)($0.09)$1.47 million$2.20 millionViewN/AView Earnings Details
8/1/2012($0.09)($0.09)ViewN/AView Earnings Details
5/2/2012Q1 2012($0.70)$0.03ViewN/AView Earnings Details
2/8/2012Q4 2011($1.20)($0.92)ViewN/AView Earnings Details
11/1/2011$0.11$0.22ViewN/AView Earnings Details
8/3/2011($0.12)($0.12)ViewN/AView Earnings Details
5/5/2011Q1 2011($1.10)($1.21)ViewN/AView Earnings Details
2/10/2011Q4 2010($1.20)($0.94)ViewN/AView Earnings Details
11/9/2010Q3 2010($1.40)($1.19)ViewN/AView Earnings Details
8/3/2010Q2 2010($1.30)($1.50)ViewN/AView Earnings Details
5/6/2010Q1 2010($1.30)($1.54)ViewN/AView Earnings Details
2/11/2010Q4 2009($1.30)($1.40)ViewN/AView Earnings Details
11/4/2009Q3 2009($1.30)($1.37)ViewN/AView Earnings Details
8/6/2009Q2 2009($1.50)($1.36)ViewN/AView Earnings Details
5/7/2009Q1 2009($1.80)($2.04)ViewN/AView Earnings Details
2/17/2009Q4 2008($2.20)($2.24)ViewN/AView Earnings Details
11/5/2008Q3 2008($2.20)($2.44)ViewN/AView Earnings Details
8/5/2008Q2 2008($2.40)($2.14)ViewN/AView Earnings Details
5/8/2008Q1 2008($2.30)($2.44)ViewN/AView Earnings Details
2/21/2008Q4 2007($2.00)($2.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vical (NASDAQ:VICL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vical (NASDAQ VICL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.58%
Institutional Ownership Percentage: 44.44%
Insider Trading History for Vical (NASDAQ:VICL)
Institutional Ownership by Quarter for Vical (NASDAQ:VICL)

Vical (NASDAQ VICL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Armistice Capital Master FundMajor ShareholderBuy100,000$1.43$143,000.00View SEC Filing  
11/10/2017Robert C MertonDirectorBuy85,700$1.75$149,975.0095,451View SEC Filing  
3/27/2017Anthony Alan RamosVPSell4,250$2.17$9,222.50View SEC Filing  
1/11/2017Lawrence Russell SmithVPSell54$2.48$133.92View SEC Filing  
1/10/2017Vijay B. SamantCEOSell5,763$2.45$14,119.35View SEC Filing  
12/22/2016Robert C. MertonDirectorSell4,000$2.24$8,960.00View SEC Filing  
12/20/2016Robert C. MertonDirectorSell4,327$2.21$9,562.67View SEC Filing  
12/13/2016Vijay B. SamantCEOSell15,699$2.39$37,520.61View SEC Filing  
12/12/2016R Gordon DouglasDirectorSell10,078$2.39$24,086.42View SEC Filing  
10/11/2016Lawrence Russell SmithVPSell54$3.05$164.70View SEC Filing  
7/11/2016Lawrence Russell SmithVPSell54$4.46$240.84View SEC Filing  
6/14/2016Robert C MertonDirectorBuy9,000$4.34$39,060.0013,978View SEC Filing  
6/9/2016Vijay B SamantCEOBuy15,700$4.72$74,104.00112,632View SEC Filing  
6/6/2016R Gordon DouglasDirectorBuy10,078$4.41$44,443.9820,906View SEC Filing  
6/3/2016Gary A LyonsDirectorBuy7,078$4.39$31,072.4214,906View SEC Filing  
3/15/2016Lawrence Russell SmithVPSell8,750$0.41$3,587.50232,331View SEC Filing  
3/3/2016Vijay B SamantCEOSell37,500$0.36$13,500.00989,226View SEC Filing  
2/19/2016Anthony Alan RamosCAOSell7,500$0.33$2,475.00View SEC Filing  
1/25/2016Anthony Alan RamosCAOSell193$0.35$67.55146,735View SEC Filing  
1/12/2016Vijay B. SamantCEOSell59,737$0.35$20,907.951,006,826View SEC Filing  
1/11/2016Lawrence Russell SmithVPSell974$0.36$350.64241,081View SEC Filing  
1/11/2016Vijay B. SamantCEOSell48,535$0.35$16,987.251,006,826View SEC Filing  
1/7/2016Vijay B SamantCEOSell75,000$0.36$27,000.001,066,563View SEC Filing  
10/12/2015Lawrence Russell SmithVPSell974$0.43$418.82242,055View SEC Filing  
10/12/2015Vijay B SamantCEOSell4,738$0.41$1,942.581,141,563View SEC Filing  
7/13/2015Igor BilinskySVPSell1,258$0.70$880.60View SEC Filing  
7/13/2015Lawrence Russell SmithVPSell974$0.70$681.80View SEC Filing  
7/13/2015Vijay B SamantCEOSell4,737$0.70$3,315.90View SEC Filing  
4/13/2015Igor BilinskySVPSell1,257$0.93$1,169.01View SEC Filing  
4/13/2015Vijay B SamantCEOSell4,738$0.93$4,406.34View SEC Filing  
3/30/2015Vijay B SamantCEOSell55,000$0.91$50,050.00View SEC Filing  
1/13/2015Vijay B SamantCEOSell4,737$1.12$5,305.44View SEC Filing  
1/12/2015Igor BilinskySVPSell1,335$1.16$1,548.60View SEC Filing  
1/12/2015Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
10/13/2014Igor BilinskySVPSell1,335$1.08$1,441.80View SEC Filing  
10/13/2014Lawrence Russell SmithVPSell1,912$1.08$2,064.96View SEC Filing  
10/13/2014Vijay B SamantCEOSell4,738$1.13$5,353.94View SEC Filing  
8/26/2014Anthony Alan RamosCAOSell12,500$1.25$15,625.00View SEC Filing  
7/14/2014Vijay B SamantCEOSell4,737$1.17$5,542.29View SEC Filing  
7/11/2014Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
4/14/2014Vijay SamantCEOSell4,738$1.16$5,496.08945,988View SEC Filing  
4/11/2014Lawrence Russell SmithVPSell1,912$1.21$2,313.52193,213View SEC Filing  
1/10/2014Anthony Alan RamosCAOBuy70,000$1.42$99,400.00102,339View SEC Filing  
1/10/2014Igor BilinskyVPBuy90,000$1.42$127,800.00143,968View SEC Filing  
1/10/2014Vijay SamantCEOBuy330,000$1.42$468,600.00950,726View SEC Filing  
9/12/2013James R SingerMajor ShareholderSell200,000$1.29$258,000.00View SEC Filing  
9/11/2013James R SingerMajor ShareholderSell300,000$1.30$390,000.00View SEC Filing  
9/10/2013James R SingerMajor ShareholderSell200,000$1.23$246,000.00View SEC Filing  
9/9/2013James R SingerMajor ShareholderSell200,000$1.22$244,000.00View SEC Filing  
9/4/2013James Singermajor shareholderSell466,000$1.24$577,840.00View SEC Filing  
8/30/2013James Singermajor shareholderSell84,000$1.31$110,040.00View SEC Filing  
8/29/2013James Singermajor shareholderSell150,000$1.30$195,000.00View SEC Filing  
8/28/2013James Singermajor shareholderSell200,000$1.31$262,000.00View SEC Filing  
8/26/2013Anthony Alan RamosCAOBuy25,000$0.01$250.0040,665View SEC Filing  
5/23/2013Robert C MertonDirectorBuy5,953$0.01$59.53View SEC Filing  
1/11/2013Alain P Phd RollandVPBuy22,092$0.01$220.92View SEC Filing  
1/11/2013Jill Marie BroadfootCFOBuy27,060$0.01$270.60View SEC Filing  
1/11/2013Vijay B SamantCEOBuy84,600$0.01$846.00View SEC Filing  
10/15/2012George J MorrowDirectorBuy6,394$0.01$63.94View SEC Filing  
9/24/2012James R SingerMajor ShareholderBuy154,333$3.99$615,788.67View SEC Filing  
8/31/2012James R SingerMajor ShareholderBuy310,000$3.51$1,088,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vical (NASDAQ VICL) News Headlines

Source:
DateHeadline
Does Vical Incorporated’s (NASDAQ:VICL) Past Performance Indicate A Weaker Future?Does Vical Incorporated’s (NASDAQ:VICL) Past Performance Indicate A Weaker Future?
finance.yahoo.com - May 16 at 9:44 AM
Vical (VICL) Rating Lowered to Sell at Zacks Investment ResearchVical (VICL) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 10 at 3:06 PM
HC Wainwright Reiterates $5.00 Price Target for Vical (VICL)HC Wainwright Reiterates $5.00 Price Target for Vical (VICL)
www.americanbankingnews.com - May 7 at 2:57 PM
Vical Incorporateds (VICL) CEO Vijay Samant on Q1 2018 Results - Earnings Call TranscriptVical Incorporated's (VICL) CEO Vijay Samant on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 9:23 AM
Edited Transcript of VICL earnings conference call or presentation 3-May-18 4:00pm GMTEdited Transcript of VICL earnings conference call or presentation 3-May-18 4:00pm GMT
finance.yahoo.com - May 4 at 9:23 AM
Vical (VICL) Announces Quarterly  Earnings Results, Misses Estimates By $0.12 EPSVical (VICL) Announces Quarterly Earnings Results, Misses Estimates By $0.12 EPS
www.americanbankingnews.com - May 3 at 4:16 PM
Vical Reports First Quarter 2018 Financial and Operational ResultsVical Reports First Quarter 2018 Financial and Operational Results
finance.yahoo.com - May 3 at 9:21 AM
Vical: 1Q Earnings SnapshotVical: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:21 AM
Vical (VICL) Upgraded to "Hold" by ValuEngineVical (VICL) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 2 at 2:36 PM
Vical (VICL) Set to Announce Earnings on ThursdayVical (VICL) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 27 at 10:23 AM
Vical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial ResultsVical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial Results
finance.yahoo.com - April 26 at 4:27 PM
HC Wainwright Analysts Give Vical (VICL) a $9.00 Price TargetHC Wainwright Analysts Give Vical (VICL) a $9.00 Price Target
www.americanbankingnews.com - April 11 at 11:52 PM
Comparing AveXis (AVXS) & Vical (VICL)Comparing AveXis (AVXS) & Vical (VICL)
www.americanbankingnews.com - April 1 at 3:10 AM
Vical (VICL) Receives Buy Rating from HC WainwrightVical (VICL) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 27 at 12:06 AM
Edited Transcript of VICL earnings conference call or presentation 15-Mar-18 4:00pm GMTEdited Transcript of VICL earnings conference call or presentation 15-Mar-18 4:00pm GMT
finance.yahoo.com - March 18 at 9:24 AM
Vical revenues up 25% in Q4Vical revenues up 25% in Q4
seekingalpha.com - March 17 at 5:03 PM
Vical (VICL) Upgraded to Buy at Zacks Investment ResearchVical (VICL) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 17 at 10:30 AM
Vical (VICL) Earns "Buy" Rating from HC WainwrightVical (VICL) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - March 16 at 1:48 PM
Vical (VICL) Issues  Earnings ResultsVical (VICL) Issues Earnings Results
www.americanbankingnews.com - March 15 at 2:25 PM
Vical Incorporated to Host Earnings CallVical Incorporated to Host Earnings Call
finance.yahoo.com - March 15 at 9:24 AM
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial ResultsVical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 8 at 5:19 PM
Stonepine Capital Management LLC Buys New Stake in Vical Incorporated (VICL)Stonepine Capital Management LLC Buys New Stake in Vical Incorporated (VICL)
www.americanbankingnews.com - March 6 at 10:02 AM
Critical Contrast: vTv Therapeutics (VTVT) vs. Vical (VICL)Critical Contrast: vTv Therapeutics (VTVT) vs. Vical (VICL)
www.americanbankingnews.com - February 21 at 7:36 AM
Vical (VICL) Commences Phase 2 Trial of VL-2397 Antifungal for Invasive AspergillosisVical (VICL) Commences Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
www.streetinsider.com - February 20 at 9:06 AM
Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive AspergillosisVical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
finance.yahoo.com - February 20 at 9:06 AM
ValuEngine Upgrades Vical (VICL) to SellValuEngine Upgrades Vical (VICL) to Sell
www.americanbankingnews.com - February 4 at 9:02 AM
Vical (VICL) Stock Rating Reaffirmed by HC WainwrightVical (VICL) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - February 1 at 1:52 PM
Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive AspergillosisVical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis
finance.yahoo.com - February 1 at 9:14 AM
Analyzing Recro Pharma (REPH) and Vical (VICL)Analyzing Recro Pharma (REPH) and Vical (VICL)
www.americanbankingnews.com - January 31 at 3:14 PM
Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical ProgramsVical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs
finance.yahoo.com - January 30 at 4:29 PM
Vical Incorporated (VICL) Major Shareholder Acquires $143,000.00 in StockVical Incorporated (VICL) Major Shareholder Acquires $143,000.00 in Stock
www.americanbankingnews.com - January 26 at 9:44 PM
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant RecipientsAstellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
finance.yahoo.com - January 22 at 5:50 PM
Vical (VICL) Upgraded to "Hold" by Zacks Investment ResearchVical (VICL) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - December 26 at 10:38 AM
What You Must Know About Vical Incorporated’s (undefined:VICL) Financial HealthWhat You Must Know About Vical Incorporated’s (undefined:VICL) Financial Health
finance.yahoo.com - December 13 at 10:54 AM
Want To Invest In Vical Incorporated (VICL)? Here’s How It Performed LatelyWant To Invest In Vical Incorporated (VICL)? Here’s How It Performed Lately
finance.yahoo.com - December 5 at 12:16 PM
Vical (VICL) Lifted to Hold at Zacks Investment ResearchVical (VICL) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - December 2 at 7:42 AM
Are Options Traders Betting on a Big Move in Vical (VICL) Stock?Are Options Traders Betting on a Big Move in Vical (VICL) Stock?
finance.yahoo.com - November 24 at 6:29 PM
ETFs with exposure to Vical, Inc. : November 21, 2017ETFs with exposure to Vical, Inc. : November 21, 2017
finance.yahoo.com - November 22 at 4:35 PM
Vical Incorporated (VICL) Earns "Buy" Rating from HC WainwrightVical Incorporated (VICL) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - November 21 at 1:16 PM
Vical Incorporated (VICL) Director Acquires $149,975.00 in StockVical Incorporated (VICL) Director Acquires $149,975.00 in Stock
www.americanbankingnews.com - November 14 at 1:32 PM
Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common StockVical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock
finance.yahoo.com - November 9 at 9:29 AM
32 Stocks Moving In Wednesdays Pre-Market Session32 Stocks Moving In Wednesday's Pre-Market Session
feeds.benzinga.com - November 8 at 8:50 AM
ETFs with exposure to Vical, Inc. : November 6, 2017ETFs with exposure to Vical, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 1:00 PM
Reviewing Vical (VICL) & Its PeersReviewing Vical (VICL) & Its Peers
www.americanbankingnews.com - October 26 at 9:20 PM
ETFs with exposure to Vical, Inc. : October 26, 2017ETFs with exposure to Vical, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 11:58 AM
Vical Incorporated (VICL) Downgraded to "Sell" at Zacks Investment ResearchVical Incorporated (VICL) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 26 at 9:00 AM
Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017
finance.yahoo.com - October 25 at 4:00 PM
Vical Incorporateds (VICL) CEO Vijay Samant on Q3 2017 Results - Earnings Call TranscriptVical Incorporated's (VICL) CEO Vijay Samant on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 24 at 4:13 PM
Vical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B InfectionVical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B Infection
finance.yahoo.com - October 24 at 11:59 AM
Edited Transcript of VICL earnings conference call or presentation 23-Oct-17 4:00pm GMTEdited Transcript of VICL earnings conference call or presentation 23-Oct-17 4:00pm GMT
finance.yahoo.com - October 24 at 11:59 AM

SEC Filings

Vical (NASDAQ:VICL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vical (NASDAQ:VICL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vical (NASDAQ VICL) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.